



PROGRAM GUIDELINES AND APPLICATION INSTRUCTIONS
STAND UP TO CANCER - PEDIATRIC NEURO-ONCOLOGY CONSORTIUM (PNOC) AND THE PNOC FOUNDATION
DIFFUSE MIDLINE GLIOMA (DMG) DISCOVERIES
CHALLENGE GRANT PROGRAM

ABOUT STAND UP TO CANCER

Stand Up To Cancer® (SU2C) raises awareness and funds research to detect and treat cancers with the aspiration to cure all patients. SU2C is a 501(c)(3) charitable organization and was initially launched as a division of the Entertainment Industry Foundation. Established in 2008 by media and entertainment leaders, SU2C utilizes these communities' resources to engage the public in supporting a new, collaborative model of cancer research, to increase awareness about cancer prevention, and to highlight progress being made in the fight against the disease. As of April 2025, more than 3,100 scientists representing more than 210 institutions are involved in SU2C-funded research projects.

The American Association for Cancer Research (AACR) is SU2C's scientific partner. A Scientific Advisory Committee, led by William G. Nelson, M.D., Ph.D., conducts rigorous competitive review processes to identify the best research proposals to recommend for funding, oversee grants administration, and provide expert review of research progress.

Current members of the SU2C Founders and Advisors Committee (FAC) include Katie Couric, Sherry Lansing, Kathleen Lobb, Lisa Paulsen, Rusty Robertson, Sue Schwartz, Pamela Oas Williams, and Ellen Ziffren. The late Laura Ziskin and the late Noreen Fraser are also co-founders. Julian Adams, Ph.D., serves as SU2C's president and CEO.

For more information visit StandUpToCancer.org, [Instagram](#), [TikTok](#), [X](#), [Facebook](#), and [YouTube](#).

ABOUT THE PEDIATRIC NEURO-ONCOLOGY CONSORTIUM AND PNOC FOUNDATION

The Pediatric Neuro-Oncology Consortium (PNOC) is a global clinical trial network dedicated to advancing biology-based clinical trials for children and young adults with brain tumors (www.pnoc.us). PNOC's mission is *"To challenge current paradigms and rapidly advance therapies that are globally accessible and transformative for children and young adults with brain tumors."* PNOC's dedicated DMG working group, *DMG Adaptive Combinatorial Therapy (DMG-ACT)*, is an internationally collaborative group led by Carl Koschmann, Javad Nazarian, and Sabine Mueller. DMG-ACT brings together basic, translational, and clinical scientists on a global scale to accelerate therapeutic advances for DMG. From research directly developed within DMG-ACT, PNOC currently leads the largest transatlantic clinical trial for DMG.

The PNOC foundation is a Platinum rated 501(c)(3) Public Charity founded in 2013 with a mission to urgently raise funds, resources and awareness to support PNOC's research and clinical trials, to ultimately improve outcomes for all children with brain tumors. Since its inception the foundation has helped PNOC launch over 40 novel Phase 1 and 2 clinical trials including some first in children and first in human trials and has played a critical role in the historic FDA approval of two new therapies for children with brain cancer. The Foundation's vision is to lose no child to brain cancer and to improve the quality of life for those fighting and surviving pediatric brain cancer.

SU2C COMMITMENT STATEMENT

SU2C is committed to reducing the burden of cancer through state-of-the-art approaches to prevention, screening, diagnosis, and treatment. Disparities in cancer persist, and mounting evidence demonstrates the need to develop precision prevention, interception, and treatment solutions for all populations. SU2C is committed to improving human health through biomedical research and addressing disparities through building relationships and partnerships with multiple stakeholders to develop and support research studies, including clinical trials, which will yield measurable outcomes for all.

PROGRAM MISSION STATEMENT

SU2C, PNOC, and the PNOC Foundation are interested in supporting highly innovative translational research that provides a step-change improvement in therapy for DMG, including diffuse intrinsic pontine glioma (DIPG), hereinafter referred to collectively as DMG. DMG primarily affects children between 5 to 10 years old but can affect younger children, adolescents, and young adults (CAYA). The program seeks translation into the clinic within 18-24 months. By fostering rigorous, translational, and accessible research, the program aims to accelerate treatments with high potential for significant increases in long-term survival and high quality of life for CAYA diagnosed with DMG. The program will also consider early-phase clinical trials representing highly innovative, out-of-the-box approaches to DMG treatment.

RESEARCH PROJECT CRITERIA

This funding call invites proposals that primarily aim to design, validate, and test ground-breaking interventions to treat DMG resulting in a step-change of long-term survival and high quality of life for CAYA patients. Projects may include:

- ➔ Pioneering therapeutic approaches as proof of concept
- ➔ Novel combination treatment strategies

Proposals should be focused on research at the preclinical research stage or later, i.e. candidate targets and/or interventions should already have been identified. The project must aim to deliver interventions to patients in a clinical research study within 18-24 months of the project start. For studies focused on earlier stages of clinical development, where later-stage trials and/or implementation of a final intervention is outside the scope of the study timeframe and budget, a clear line of sight to the following steps required for intended implementation should be articulated. All proposals should align with SU2C and PNOC's mission.

Funding is available for up to two Challenge Grants. Towards the end of the grant term, selected team(s) that successfully demonstrate high potential for treatment with long-term survival and high quality of life for CAYA patients with DMG may be eligible for larger-scale funding to support an early phase clinical trial or an expansion of an early phase trial.

APPLICATION DEADLINE

The Full Application shall be submitted by Wednesday, September 30, 2026, at 11:59 pm midnight Pacific Standard Time (PST). Teams selected as finalists will be invited to present the application at a virtual selection meeting to be held the week of November 2, 2026. The selected team will be notified early December 2026 with anticipated project start dates in March 2027.

See the section "Application Instructions" on page 10 for further information.

TEAM COMPOSITION AND MEMBER ELIGIBILITY CRITERIA

The Team must include a Team Leader and Team Co-Leader. Other potential team roles are defined below. No more than two additional Team Principals may be included, with a maximum of four participating institutions.

Definitions

1. **Team Leader (TL)** (required): The Team Leader is the person responsible for the scientific and technical direction of the proposed research project, contractual and financial obligations, and other organizational assurances/certifications. The TL must ensure that the Team complies with the terms and conditions of the award and will be the primary contact person for SU2C science staff.
2. **Lead Institution** is the organization at which the Team Leader is employed, and it will be legally and financially responsible for the conduct of Team activities supported by the funds.
3. **Team Co-leader (TC)**: A Team Co-leader is designated by the Team Leader to assist in directing the scientific and technical work of the Team. A Co-leader serves as an alternate contact person for SU2C science staff.
4. **Team Principal (TP)**: Team Principal(s) is a senior investigator(s) who will lead a component(s)/subproject(s) of the Team research project.
5. **Project Manager**: The Team Project Manager (PM) is the administrative leader of the Team and the key administrative contact for the Team with SU2C. The PM is responsible for the coordination of all team efforts to consistently maintain a high level of functionality, collaboration, and communication. The PM coordinates the Patient Advocates and the scientific reporting, and, where appropriate, assists the Team in developing a plan for clinical trial accrual, diversity, and tracking.
6. **Patient Advocates**: Patient Advocates bring the perspectives of those affected by cancer (e.g., patients, survivors, caregivers) to the work of Team. They enable the Team scientists to see their research through the eyes of the target audience and integrate these perspectives into the direction of the Team research. Patient Advocate members do not represent the viewpoints or issues of any advocacy organization or their individual personal issues. Where appropriate, Patient Advocates also work with the Team in developing a plan for clinical trial accrual, diversity, and tracking, including measures to ensure recruitment and retention of diverse participants. If you need assistance with the identification of qualified Patient Advocates for your application, you may contact proposals@su2c.org.
7. **Investigators**: Senior investigators, other than the TL, TC, and TPs, who are employed at the TL, TC, or TP institutions and contribute substantively to the Team research project, may be included as members of the Team.
8. **Early-Career Investigators**: Junior faculty (i.e. independent investigators who have completed their training no more than seven years prior to the start of the award term), postdoctoral fellows, clinical research fellows, or any other researchers-in-training who are working under the direction of a scientific mentor (i.e., a TL, TC, TP, or Investigator) may be included as members of the Team.
9. **Collaborator**: An Investigator who is not employed by a participating institution and is unfunded in this project budget yet makes valuable contributions to the Team.
10. **Budget and Contract contact** (required per institution): For each participating institution/clinical trial site, provide at least two officials responsible for agreements.
11. **Other (Scientific/Technical)**: Any person providing scientific or technical support, such as Lab managers and technicians
12. **Other (Administrative)**: Any person providing administrative support such as Administrative assistants
13. **Public Information Officer (PIO)** (required per institution): The PIO is the communications coordinator or spokesperson for the institution.

Team Member Eligibility Requirements

1. There is no limit to the number of Investigators from each of the institutions that may contribute to the project.

2. The TL, TC, and TPs, must have acquired a doctoral or medical degree and must be independent investigators affiliated with an academic, medical, or research institution. Individuals on the FDA Debarment List may not apply.
3. Research may be carried out internationally. There are no citizenship or residency status restrictions for team members.
4. The TL and TC are expected to each dedicate at least 20 percent (or 40 percent combined) of their time and effort to the Team research project.
5. TPs must each dedicate at least 10 percent of their time and effort to the Team research project.
6. No Team will have more than one Key Personnel (TL, TC, or TP) from any given institution at the time of their initial appointment on the Team. No more than two Key Personnel may be from affiliated institutions. It is expected that additional Investigators from the TL, TC or TP institutions may be involved in the Team research project in some other capacity, and there is no limit to the number of Investigators from each of these institutions that may contribute to the Team project.
7. Employees or subcontractors of for-profit industry are eligible to serve as a TL, TC, or TP, to foster the development of novel strategies.
8. Early Career Investigators are not eligible to serve as a Team Leader, Co-leader, or Principal; however, their participation in the Team research projects is highly encouraged.
9. Neither members of the SU2C Scientific Advisory Committee, PNOC leadership, or DMG-ACT leadership nor members of their individual laboratories are eligible for funding as part of this program.
10. Key Personnel should not be funded on more than one SU2C-sponsored Team grant (Dream Team or Research Team).
11. No more than 50 percent of the Principals (including Leader and Co-leader) from a previous Team may apply as a group on a new Team proposal.

Applicants with a question about the eligibility requirements are encouraged to contact SU2C at proposals@su2c.org prior to submitting the proposal.

EVALUATION OF PROPOSALS

The Selection Committee will review the applications and consists of highly accomplished experts in brain cancer, senior laboratory researchers and physician-scientists who are respected internationally for their own accomplishments in cancer research and as leaders in the field, as well as at least one Patient Advocate.

The Selection Committee will consider the following criteria when evaluating the proposals:

- Scientific merit of the proposed research project and translational potential of the research
- Significance of the proposed research
- Novelty of the hypothesis or methodology
- Degree to which the studies have the potential for producing a step-change in DMG treatment resulting in long-term survival and high quality of life for patients
- For preclinical projects, likelihood that the project will translate into the clinic within 18-24 months
- For early phase clinical trials, novelty of therapeutic strategy and supporting data
- Team leadership qualities
- Involvement of patient advocates and/or community members in study design and implementation
- Alignment with the SU2C and Program Commitment Statement
- Likelihood that the research project will achieve its stated goals given the budget requested, institutional environments, and other resources available
- Likelihood that patient enrollment to applicable clinical trial(s) will be completed within the timeframe of the grant
- Whether adequate institutional and/or financial support exists to sustain the research project
- The cost effectiveness of the budget

- Team leadership qualities (TL, TC, TPs): Willingness to collaborate, their research credentials, their unique contributions to the Team research project, demonstrated ability to bring together and lead an interdisciplinary team of experts to a successful conclusion, expertise in the field, and commitment to translational cancer research with clear emphasis on near-term clinical application
- A clear commitment by the Team that all data resulting from their work will be available to the scientific community at large at the earliest opportunity, as allowed under patient privacy and other applicable laws
- Likelihood that the research project will achieve its stated goals given the timeframe of the grant, budget requested, institutional environments, and other resources available

GRANT TERMS

Changes to application. Applicants are not allowed to change the project nor the Team members proposed in the Full Application. If changes are necessary, prior written approval from SU2C is required.

Contracts. A Grant Agreement will be executed between SU2C and the Team Leader's Institution, referred to as the Lead Institution. The Lead Institution must serve as the administrator of the funds and hold responsibility for the disbursement of the funds, management of the budget, and provision of progress and financial reports. It is expected that the Lead Institution will enter into subcontracts with the institutions of the Principal, which include all terms that are applicable to the Team Institution's or Team Member's performance of the project, and assurances that these contractual agreements have been executed will be required for continuation of funding.

Commencement. The Team Leader will commence upon execution of the contract agreement with the lead institution. Stand Up To Cancer retains the right to terminate the grant agreement if the research project is not commenced in a timely manner.

Budget. Teams may apply for total support up to \$1,000,000 for up to a 2-year term. The templates provided with the application should be used to complete a detailed budget. SU2C strongly advises a limited 6-month budget as past Teams over-allocate funds in this timeframe. All funding is contingent upon: (1) milestones and deliverables being appropriately selected and satisfactorily pursued and achieved, as determined by SU2C, the SU2C Scientific Advisory Committee, the Selection Committee, the Review Team, and PNOC and DMG-ACT leadership; and (2) Lead Institution compliance with all applicable laws and financial accounting requirements.

Use of Funds. Funds may be used for direct research expenses attributable to the proposed research, which may include:

- Expenses related to the project and its implementation, including, for example, regulatory filings, sample collection, shipping and handling, database management, clinical coordinators, informed consent
- A percentage of the salary and benefits expenses (limited to 20 percent of the total budget) of senior investigators (NIH cap applies)
- A percentage of salary and benefits expenses of the Early Career Investigators on the Team
- Salary and benefits expenses for research assistants or technicians
- Equipment, supplies, and other laboratory or clinical expenses
- Travel expenses relevant to the Team research project, including travel to the institutions of the Team Leader/Principal and travel to meetings with the committees, as well as to the annual SU2C Scientific Summit and PNOC Annual Meetings
- Expenses (limited to a total of \$5,000/year) related to publication page charges and/or the presentation of research data at scientific meetings or through other means that will contribute to the dissemination of the scientific knowledge derived from the proposed research

The funds may not be used for salary or benefits of any Collaborators from a government institution/agency, or for any research expenses related to the Team project that are incurred by these individuals. Tuition and professional membership dues are not allowable expenses.

Any indirect costs charged by the institutions will be negotiated to a minimum, but in no event will there be permitted a charge of more than 10 percent of the total budget.

Payments. The payment schedule between the Team and Stand Up to Cancer will be delineated in the grant agreement.

Reporting Requirements. Progress and financial reports, submitted each year on July 15 and January 15, shall highlight the accomplishments of that specific time period bearing in mind the pre-defined Milestones and Deliverables of the Team. Progress Reports will be reviewed by SU2C, PNOC and DMG-ACT leadership, and a Review Team drawn from the Selection Committee. The Team Leader and Co-Leader will be required to attend and present at biannual reviews: one annually in-person in January/February at the SU2C Scientific Summit and another virtually during the summer. They will also be expected to attend at least annual PNOC meetings to present research updates and progress towards study objectives.

SU2C may withhold release of any or cancel future Funds until the reports have been filed and approved. Failure to address deficiencies, meet collaborative agreement requirements, or achieve the pre-defined Milestones and Deliverables may result in discontinuation of the funding.

Teams must meet three times a year, either in person, by teleconference, or by videoconference, to review progress and, if necessary, adjust research plans. Two of the required meetings can be fulfilled prior to the semi-annual reviews, where Team Leaders meet with the Review Team and all other Team members, following the submission of Progress Reports, to thoroughly discuss the Teams' progress. The review meeting schedule will be an appendix to the Team contract.

A final written progress and financial report shall be submitted no later than sixty (60) days after the ending date of the collaborative agreements term. The reporting materials must include all project components. The Team Leader may be asked to attend a follow-up meeting. The financial report shall document the expenditure of funds, the purpose of such expenditures, and how actual expenditures compared to the budget for the funding period.

SU2C and PNOC/PNOC Foundation may use all or portions of the report for public dissemination, such as within SU2C and PNOC/PNOC Foundation newsletters or websites, or in other similar manners, in consultation with the Team Leader.

Subject to Applicable Laws, and upon SU2C's reasonable request, Lead Institution agrees to provide access to SU2C or its designee to audit Lead Institution's financial books and records which are directly related to the project.

The Lead Institution agrees that SU2C will be permitted sufficient access to monitor the progress of the project at mutually agreeable times, including permitting any authorized SU2C staff member to monitor research on the project at the Lead Institution or other site where research on the project is being conducted.

Publications and Acknowledgment of Support. Any publications resulting from research funded in whole or in part by the agreement must cite SU2C and PNOC in the acknowledgment: "Supported by funds from Stand Up To Cancer, the Pediatric Neuro-Oncology Consortium (PNOC), and PNOC Foundation." Copies of such publications shall be forwarded to SU2C and PNOC after acceptance but before publication.

No external announcement, press release, or other public statement shall be made by Lead Institution, Team Institutions, or Team Members to publicize their involvement with SU2C, PNOC, or PNOC Foundation regardless of the medium used, without prior written approval from SU2C, PNOC, and PNOC Foundation.

Lead Institution, Team Members, and Team Institutions must obtain prior written approval from SU2C, PNOC, and PNOC Foundation for any use of the SU2C, PNOC, or PNOC Foundation logos, trademarks, or service marks, respectively.

Intellectual Property. SU2C, PNOC, and PNOC Foundation must be notified of any discovery that is protectable under applicable law (e.g. patentable), that is discovered in the course of the research funded through this agreement. SU2C, PNOC, and PNOC Foundation shall have no responsibility or interest in the protection of, commercialization, or licensing of intellectual property resulting from the Team. The Team Leader and the Lead Institution shall notify SU2C, PNOC, and PNOC Foundation of the granting of each patent or other legal protection and of all commercial exploitation of any Invention.

Ethical and Legal Requirements. The Lead Institution will certify that the Team Member(s) which it employs, and, to the best of its belief, all other Team Members are not presently debarred, suspended, proposed for debarment, declared ineligible, or voluntarily excluded from covered transactions by any government department or agency; have not, within the 4-year period preceding the effective date, been convicted of, or had a civil judgment rendered against them for: 1) Committing fraud or a criminal offense in connection with obtaining, attempting to obtain, or performing a public transaction or contract under a public transaction; 2) Violating an antitrust statute; 3) Embezzlement, theft, forgery, bribery, falsification or destruction of records; 4) Making false statements or receiving stolen property; 5) Are not presently indicted or otherwise criminally or civilly charged by a government entity with commission of any of the offenses enumerated above; and 6) Have not, within a three (3) year period preceding the Effective Date, had any public transaction terminated for cause or default.

Lead Institution, Team Institutions, and Team Members have an affirmative duty to protect all Grant Funds from misuse by ensuring the integrity of the project. This duty involves discouraging and addressing research misconduct, meaning fabrication, falsification, or plagiarism in proposing, performing, or reviewing research or in reporting research results. In furtherance of this responsibility, the Lead Institution shall, and shall contractually require each Team Institution to 1) Have written policies and procedures for addressing allegations of research misconduct; 2) Respond to each allegation of research misconduct in a thorough, competent, objective and fair manner; 3) Foster a research environment that promotes the responsible conduct of research, discourages misconduct, and deals promptly with allegations or evidence of possible misconduct; 4) Take all reasonable steps to protect the positions and reputations of good faith complainants, witnesses and committee members and protect them from retaliation; 5) Fully investigate all good faith allegations of misconduct and complete reasonably promptly such investigations by determining whether or not such misconduct occurred and imposing sanctions where appropriate; and 6) Preserve the confidentiality of any allegations of misconduct and subsequent investigation.

Within ten (10) days of a finding of misconduct against any Team Member, Lead Institution must file a report with pertinent details describing the misconduct's potential effects on the conduct of the project to SU2C. Notwithstanding any disciplinary action imposed by the institution involved, SU2C will consider the situation and take any action it deems appropriate, in its sole discretion, including termination of the Team Member's involvement or termination of the project.

Financial Conflicts of Interest. Lead Institution shall maintain and shall take reasonable steps to contractually obligate all Team Institutions to maintain an appropriate written, enforced policy on conflict of interest that

complies with 42 C.F.R. Part 50, Subpart F (§§ 601-606). The Lead Institution shall require each Team Institution to inform its employees of the Team Institution's policy and the individual employee's reporting obligations.

Compliance with SU2C Policies. Applicants agree to comply with SU2C's policies on (1) Tobacco Industry Funding and Material Support and (2) Bullying and Harassment, which are included as downloads in ProposalCentral.

Insurance. Insurance shall be maintained by the Team Members and Institutions for professional liability and comprehensive general liability insurance, on an "occurrence" basis, against claims for "personal injury" liability, including bodily injury, death, or property damage liability. Such insurance shall be primary and noncontributory with any other insurance carried by SU2C and shall provide appropriate waivers of subrogation against SU2C, and its directors, committee members, employees, affiliates, and agents.

Notification of Changes. The Team Leader is responsible for notifying SU2C immediately of any changes in the composition of the Team and changes in the position or institution of any of the Team Members. SU2C may not accept proposals to change the research project from that described in the application and may terminate the funds.

Post-award, Lead institution may rebudget funding within and between budget categories in order to meet unanticipated needs and to make other post-award changes, provided that the total budget amount does not change. Additionally, Lead Institution may restrict Teams Institutions' authority to make budget changes without its prior written approval. However, Lead Institution must obtain SU2C's prior written approval for any significant rebudgeting, which occurs when the direct costs allocated to a single budget category are increased or decreased by more than fifteen percent (15%) of the total budget period award. If SU2C's approval is required, it must be requested in advance of making such change.

Organizational Assurances. The Team Leader and Lead Institution are responsible for ensuring that organizational assurances/certifications from all Team Member Institutions are obtained.

For research involving human subjects, the appropriate Team Member(s) and U.S. Institution(s) shall certify that:

- a. Prior to the initiation of human research, the proposed research project has been reviewed and approved in writing by an Institutional Review Board ("IRB") constituted in accordance with current regulations promulgated by the United States Department of Health and Human Services ("HHS") and registered with HHS.
- b. The Team Member(s) shall secure a legally acceptable informed consent from all human subjects taking part in any research funded in whole or in part by SU2C in accordance with and to the extent required by current regulations promulgated by the United States Department of Health and Human Services and approved by HHS. IRB approval for human subjects research should be submitted to SU2C, and funds for human subjects research will not be released unless and until proof of all IRB certifications is received by SU2C. Prior IRB approval for another project cannot be substituted but can be officially amended to include the proposed project.

For research involving animals, the Institution(s) shall ensure compliance with applicable chapters of the Public Health Service Animal Welfare Policy, the NIH Manual for Grants and Contracts, and any and all requirements of the Institution concerning animal welfare. Certification by the Institution Animal Care and Use Committee (IACUC) or equivalent shall be documented by submitting a copy of the institutional letter of approval, which identifies the Team Member(s) responsible for the project, the Team research project title, SU2C as the funding agencies, and the date of approval, and is signed by the IACUC Chair or equivalent Institution official. Prior IACUC certification for another project cannot be substituted but can be officially amended to include the proposed project.

Team Members at non-U.S. institutions must adhere to ethical standards for the protection of human and animal subjects that are at least equivalent to U.S. standards and to the legal requirements of the country of origin. Certification of ethical standards review and approval should be documented by submitting a letter, which cites all relevant approval and license numbers and dates required by the country of origin. In the absence of an official ethical review board (or equivalent) or legal requirements, the Team Member(s) must agree in writing to adhere at minimum to the World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects.

APPLICATION INSTRUCTIONS

The Full Application shall be submitted through ProposalCentral by Wednesday, September 30, 2026, at 11:59pm midnight Pacific Daylight Time. Teams invited to present at the virtual Selection Meeting will be informed on or before Wednesday, October 21, 2026. The Team Leader and Co-Leader of the finalist teams will be required to present during the virtual Selection Meeting to be held the week of November 2, 2026. The selected team will be notified in early December 2026 with anticipated project start dates in March 2027.

The Full Application includes the following elements:

- Title Page
- Signatures Pages: Signature pages must be submitted for every Institution requesting SU2C/PNOG Foundation funds through this grant application. The Team Leader, Team Principal, and Institutional Budget and Contract Contacts must be included in the Signature Pages.
- Lay Abstract (limited to 1/2 page)
- Scientific Abstract (limited to 1/2 page)
- Research Proposal – to be uploaded as an attachment (limited to 3 pages; include the following information) (Template on Proposal Central)
 - Background and Rationale
 - Specific Aims
 - Research Design and Methods
 - Statistical Plan
 - Data/Sample Access
 - Projected Timeline and Milestones
 - Significance and Therapeutic Impact
 - Collaboration/Team Members
 - Data Sharing Plan
- Facilities – to be uploaded as an attachment (limited to 1 page per Institution)
- References – to be uploaded as an attachment (no page limit)
- Other Support
- Budget Justification: – to be uploaded as an attachment
 - Limited to three (3) pages per institution. Detailed justification of the separate budget requests for expenses related to the research components/subprojects conducted by the Team Leader and Team Principal is required for all items of the equipment costing over \$1,000, and the need for personnel, supplies, and other items. Provide the names of individuals whose salaries will be supported by the grant funds and justify the amount of support requested. If requesting “Other Expenses,” a thorough list of these expenses along with the justification is required.
- Milestones and Deliverables Timeline – to be uploaded as an attachment (Template on Proposal Central)
- Requested funding and required regulatory approvals per Specific Aim
- Budget (should not exceed \$1,000,000 USD): See sections “Budget” and “Use of Funds” on page 5-6 for additional information.
 - Information required for ProposalCentral includes:
 - Total Budget per Year
 - Budget per Institution (complete for every institution)
 - Total Budget per Institution
- Team Roster: See section “Eligibility Criteria” on page 4 for additional information.
- CVs for Team Leadership– to be uploaded as an attachment (Team Leader, Team Principal; NIH Biosketch preferred but not required; no template is provided; do not exceed five (5) pages per individuals)
- Letters of Support – to be uploaded as an attachment
 - Letters from Leadership at each Institution/Company involved in the Team

Other Application Information

Teams are required to have a Team Leader. Projects should be planned for up to 2 years. The proposed budget should not exceed \$1,000,000 US dollars total.

Application Submission

Full Applications will be submitted through the ProposalCentral portal (proposalcentral.com) using the instructions, fields, and templates provided there. An email will be sent to confirm receipt of your online submission.

Changes to the Application

Following the submission of an application, the Team Leader should notify SU2C in writing of (1) any changes of address, email, or phone number for any Team member, (2) any changes in institution for any Team member, or (3) withdrawal of the application for any reason.

NOTIFICATION

Teams invited to present at the virtual Selection Meeting will be informed on or before Wednesday, October 21, 2026. The selected team will be notified in early December 2026 with anticipated project start dates in March 2027.

INQUIRIES

SU2C is administering this grant program. Inquiries about the program guidelines, eligibility requirements, and application materials can be directed to SU2C Science at: proposals@su2c.org

Virtual RFA discussion meetings will be held on Friday, August 14, 2026, and Wednesday, September 9, 2026. Contact proposals@su2c.org no later than Thursday, August 13, 2026, or Tuesday, September 9, 2026, for respective meeting details.